Additionally, the treatment with an FK506-binding protein-like (FKBPL)-based peptide repressed a subpopulation of endocrine therapy-resistant CSC in ER+ breast cancer by interfering with DLL4 and Notch4 signaling [145]. The gene discussed is DLL4; the disease is breast cancer.